Portfolio newsInvesting in Oxford University spin-outsOSEM – Oxford Spin-out Equity ManagementOxford University’s commitmentto technology transfer is wellknown, and <strong>Isis</strong> <strong>Innovation</strong> whichmanages such activity is oneof Europe’s leading technologytransfer vehicles. The Universityis now taking steps to ensure thatits shareholdings in companieswhich are established aresupported from within itsorganisation. Oxford Spin-outEquity Management (OSEM)Dr Chris Towler, Director, OSEMwas established in August 2008to manage the University’s interests in its spin-out companiesand seek ways of maximising the value of its equity stakes.OSEM is a unit of the University, with a direct reporting lineto the Director of Finance, although it works closely with <strong>Isis</strong>.OSEM’s role in managing interests within the portfolio ofestablished spin-out companies starts after seed-funding hasbeen secured and the initial company management teamestablished. OSEM thereafter maintains relationships withthe developing companies to support their commercialisationobjectives and assess opportunities for further investment bythe University. To this end, OSEM manages an investmentfund, which currently stands at around £2.5 million.While OSEM is likely to remain a small unit, its two Executives,Dr Chris Towler and James Mallinson, have considerableexperience in the industrial, financial and higher educationsectors. With the recent appointment of an assistant, theOSEM team aims to provide an effective and well-informedconduit between the University and the companies in whichit holds shares.The portfolio of established spin-outs comprises 47companies, a large percentage of which operate in thehealthcare / medical arena. However, almost all aspects ofthe university’s rich research programme are represented.Products of engineering sciences, software innovation andapplications relevant to the environment and industrialprocesses are all present.In this edition of <strong>Isis</strong> News, we have chosen to highlight twocompanies which have made exciting progress in recentmonths and which exemplify the overall objectives of Oxford’stechnology transfer ambitions. Looking at the existingportfolio and the pipeline of emerging commercialisationopportunities, we are confident that there will be noshortage of interesting developments to report in futureeditions of <strong>Isis</strong> News.Ways in which OSEM adds value:Working with company boards to deliver consents andsupport and participate in development of strategies,including exitUsing its own networks to create access to funding orpeopleUsing its experience to challenge management teams toaddress issues and risksAppointing University-nominated DirectorInvesting on behalf of Oxford UniversityRealising assets for University (e.g. sales of shares;negotiations of exits)OSEM was established to manage the University’s interestsin its spin-out companies and seek ways of maximising thevalue of its equity stakescontactDr Chris TowlerDirector, OSEMT 01865 280918E chris.towler@isis.ox.ac.uk20
Summit looks EastSummit Corporation plc (AIM: SUMM), a leading UKbiotechnology company, has announced a non-exclusiveresearch agreement with the healthcare and pharmaceuticalcompany Johnson & Johnson PTE Ltd in Singapore toexplore and develop the use of zebrafish drug screening indrug discovery and development.Under the terms of the agreement, Summit will receivean undisclosed amount over three years to support thedevelopment of new assays using the zebrafish platform.The platform is used to screen drug candidates for a broadrange of toxicity and safety issues. The research will beundertaken at a new state-of-the-art zebrafish facility inSingapore and will be established and maintained bySummit as part of this agreement.Summit expects the facility in Singapore to be fullyoperational early in 2009, when it will primarily undertakeassay development work in accordance with the agreement.In addition, Summit will use Singapore, already a centre ofexcellence in zebrafish research, as a base to target newmarkets in the Far East and expand its current zebrafishscreening services business.Steven Lee, PhD, Chief Executive Officer of Summitcommented: “I am pleased Summit will be extending theexcellent relationship we have established in our zebrafishtechnology through the signing of this longer-term agreement.This partnership is an important milestone for Summit and isa natural follow-on from previous pilot studies conductedwith Johnson & Johnson PTE Ltd. Beyond this agreement,I anticipate additional assay screening revenues and assaydevelopment work plus further services revenues from otherthird party clients.“I believe this agreement demonstrates continued interest inthe value zebrafish can bring to the drug discovery processand will enhance one of our two technology platforms thatsupport our drug programme business. We look forward toworking closely with them on developing this technologyover the next few years.”Development of a new class of antibiotics to treat MRSAResearch published in Science in September 2008 reportsProlysis’s discovery of a new class of drugs that kill MRSA inthe laboratory and could form the basis of new treatmentsto fight the infection.Scientists from Prolysis, a spin-out from the Sir WilliamDunn School of Pathology at the University of Oxford, andcolleagues have created a class of drugs that selectivelyblock the action of a protein called FtsZ, which bacteria needin order to grow. The drugs kill a range of bacteria, includingmethicillin-resistant and multi drug-resistant Staphylococcusaureus (MRSA).The research was supported by the Wellcome Trust throughits Seeding Drug Discovery programme, and by a LINKgrant in applied genomics from the Biotechnology andBiological Sciences Research Council (BBSRC) and theformer Department of Trade and Industry (DTI), now DIUS.This has been in addition to significant equity investment inProlysis led by East Hill of Boston.Lloyd Czaplewski, Director of Research at Prolysis, said: “Bytargeting this specific and essential bacterial protein, wehave developed a class of drugs with a novel mechanismof action and the potential to treat MRSA and similarinfections. Partnered with rapid diagnostics, it mightalso be used to prevent many of these infections in ourhospitals and care homes.The zebrafish platformis used to screen drugcandidates for a broad rangeof toxicity and safety issuesSummit (originally called Vastox Limited, and founded in 2003)is a spin-out from the Chemistry Department of the Universityof Oxford. Summit floated on AIM in October 2004.contactJames MallinsonPortfolio Manager, OSEMT 01865 280903E james.mallinson@isis.ox.ac.uk21